CRISPR, Genome Editing Market

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the CRISPR-based genome editing services market in the short to mid-term, and long term.

Chapter 3 provides a brief overview, history and applications of genome editing. It includes detailed discussion on the different types of currently available genome editing techniques. In addition, the chapter provides details of CRISPR technology along with the information on role of CRISPR / Cas in bacterial adaptive immunity, key CRISPR / Cas systems and components of CRISPR / Cas system. Further, it includes details on protocol associated with CRISPR-based genome editing, applications of CRISPR and associated key challenges and future perspectives.

Chapter 4 provides a comprehensive view on the current landscape of CRISPR-based genome editing service providers. It includes information related to over 80 companies that claim to offer CRISPR-based genome editing services, featuring an in-depth analyses of the players based on their service offering including gRNA service (gRNA design and gRNA construction), availability of gRNA format (plasmid, lentivirus, AAV, adenovirus and others), type of endonuclease (Cas9, Cpf1 and others), availability of Cas9 format (mRNA, plasmid, lentivirus, AAV, protein and others), type of cell line engineering offering (knockout, knockin, tagging / reporters and others), type of cell line (stem cell lines, human cell lines, other mammalian cell lines and others (microbial, insects and others)), type of animal model generation offering (mice / mouse, rat, zebrafish, C.elegans and others), availability of CRISPR libraries and important service provider details (year of establishment, headquarter location(s), company size).

Chapter 5 features a comprehensive 2X2 analysis offering a comparative summary of all the CRISPR-based genome editing service providers that we came across during our research. The analysis compares the aforementioned companies within three peer-groups, established based on size of employee base (small-sized (1-200 employees), mid-sized (>201-1,000 employees) and large (>1,000 employees)). The companies were compared based on their genome editing capabilities (including gRNA service(s), endonuclease service(s), cell line service(s), animal model generation service(s), CRISPR library(s)) and supplier power.

Chapter 6 features profiles of CRISPR-based genome editing service providers (shortlisted based on strength of service portfolio). Each profile features an overview of the company, its financial performance (if available), brief details of genome editing service portfolio, recent developments and an informed future outlook.

Chapter 7 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed since 2006 related to CRISPR technology. The analysis also highlights the key trends associated with these patents, including type of patent (granted patent, patent application and others), publication year and application year, geography (North America, Europe, Asia-Pacific and Rest of the World), CPC symbols (Top 15 CPC symbols), key focus areas, leading industry / non-industry players, patent benchmarking analysis and patent valuation analysis.

Chapter 8 provides information on close to 2,200 grants that were awarded to research institutes engaged in projects related to CRISPR technology, between 2015 and 2019 (till September). The analysis also highlights important parameters associated with grants, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.

Chapter 9 provides details of innovative technology platforms (such as integration of delivery platforms, enzyme technologies, protein technologies and others with the fundamental CRISPR technology) to improve CRISPR processes. It includes the list of companies that are focused on the development of these technologies along with details on a number of parameters, such as year of establishment, headquarter location(s), company size, company expertise and technology details (name, focus and key features). In addition, it includes tabulated profiles of key technology providers, with details on company overview, funding and collaboration instances. Further, the chapter highlights a list of companies that offer CRISPR design tools and kits.

Chapter 10 features an insightful analysis, highlighting potential strategic partners (for instance, drug developers) for CRISPR-based genome editing service providers, based on multiple parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area. The analysis aims to provide the necessary inputs to the stakeholders, enabling them to make the right decisions to conduct research work with the help the appropriate partner entities.

Chapter 11 features a comprehensive market forecast, highlighting the future potential of CRISPR-based genome editing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] type of services (gRNA construction, cell line engineering and animal model generation), [B] type of cell line (mammalian, microbial, insect and others) and [C] different global regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 12 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall CRISPR-based genome editing services market. 

Chapter 13 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the CRISPR technology domain. 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 15 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Tables of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Context and Background
3.2. Overview of Genome Editing
3.3. History of Genome Editing
3.4. Applications of Genome Editing
3.5. Genome Editing Techniques
 
3.5.1. Mutagenesis
3.5.2 Conventional Homologous Recombination
3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination
3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)
 
3.5.5. Protein-based Nuclease Systems
3.5.5.1. Meganucleases
3.5.5.2. Zinc Finger Nucleases
3.5.5.3. Transcription Activator-like Effector Nucleases
 
3.5.6. DNA Guided Systems
3.5.6.1. Peptide Nucleic Acids
3.5.6.2. Triplex Forming Oligonucleotides
3.5.6.3. Structure Guided Endonucleases
 
3.5.7. RNA Guided Systems
3.5.7.1. CRISPR-Cas9
3.5.7.2. Targetrons
 
3.6. CRISPR-based Genome Editing
3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria
3.6.2. Key CRISPR-Cas Systems
3.6.3. Components of CRISPR-Cas System
3.6.4. Protocol for CRISPR-based Genome Editing
 
3.7. Applications of CRISPR
3.7.1. Development of Therapeutic Interventions
3.7.2. Augmentation of Artificial Fertilization Techniques
3.7.3. Development of Genetically Modified Organisms
3.7.4. Production of Biofuels
3.7.5. Other Bioengineering Applications
 
3.8. Key Challenges and Future Perspectives
 
4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape
4.2.3. Analysis by Type of Service Offering
4.2.4. Analysis by Type of gRNA Format
4.2.5. Analysis by Type of Endonuclease
4.2.6. Analysis by Type of Cas9 Format
4.2.7. Analysis by Type of Cell Line Engineering Offering
4.2.8. Analysis by Type of Animal Model Generation Offering
4.2.9. Analysis by Availability of CRISPR Libraries
4.2.10. Analysis by Year of Establishment
4.2.11. Analysis by Company Size
4.2.12. Analysis by Geographical Location
4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters
 
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape
5.4.1. Small-sized Companies
5.4.2. Mid-sized Companies
5.4.3. Large Companies
 
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Applied StemCell
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Recent Developments and Future Outlook
 
6.3. BioCat
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Recent Developments and Future Outlook
 
6.4. Biotools
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook
 
6.5. Charles River Laboratories
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Recent Developments and Future Outlook
 
6.6. Cobo Scientific
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook
 
6.7. Creative Biogene
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Recent Developments and Future Outlook
 
6.8. Cyagen Biosciences
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Recent Developments and Future Outlook
 
6.9. GeneCopoeia
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Recent Developments and Future Outlook
 
6.10. Horizon Discovery
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Service Portfolio
6.10.4. Recent Developments and Future Outlook
 
6.11. NemaMetrix
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Recent Developments and Future Outlook
 
6.12. Synbio Technologies
6.12.1. Company Overview
6.12.2. Service Portfolio
6.12.3. Recent Developments and Future Outlook
 
6.13. Thermo Fisher Scientific
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. Service Portfolio
6.13.4. Recent Developments and Future Outlook
 
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
 
7.3. CRISPR-based Genome Editing: Patent Analysis
7.3.1. Analysis by Application Year and Publication Year
7.3.2. Analysis by Geography
7.3.3. Analysis by CPC Symbols
7.3.4. Emerging Focus Areas
7.3.5. Leading Players: Analysis by Number of Patents
 
7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Patent Valuation Analysis
 
8. ACADEMIC GRANT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Grants Awarded by the National Institutes of Health for CRISPR-based
8.3.1. Year-wise Trend of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institutes
8.3.4. Analysis by Support Period
8.3.5. Analysis by Funding Mechanism
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Grant Activity
8.3.8. Analysis by Recipient Organization
8.3.9. Regional Distribution of Grant Recipient Organization
8.3.10. Prominent Project Leaders: Analysis by Number of Grants
8.3.11. Emerging Focus Areas
8.3.12. Grant Attractiveness Analysis
 
9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES / SYSTEMS AND TOOLS
9.1. Chapter Overview
9.2. CRISPR-based Technology Providers
9.2.1. Analysis by Year of Establishment and Company Size
9.2.2. Analysis by Geographical Location and Company Expertise
9.2.3. Analysis by Focus Area
9.2.4. Key Technology Providers: Company Snapshots
9.2.4.1. APSIS Therapeutics
9.2.4.2. Beam Therapeutics
9.2.4.3. CRISPR Therapeutics
9.2.4.4. Editas Medicine
9.2.4.5. Intellia Therapeutics
9.2.4.6. Jenthera Therapeutics
9.2.4.7. KSQ Therapeutics
9.2.4.8. Locus Biosciences
9.2.4.9. Refuge Biotechnologies
9.2.4.10. Repare Therapeutics
9.2.4.11. SNIPR BIOME
9.2.5. Key Technology Providers: Summary of Venture Capital Investments
9.3. List of CRISPR Kit Providers
9.4. List of CRISPR Design Tool Providers
 
10. POTENTIAL STRATEGIC PARTNERS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Potential Strategic Partners for Genome Editing Service Providers
10.3.1. Key Industry Partners
10.3.1.1. Most Likely Partners
10.3.1.2. Likely Partners
10.3.1.3. Less Likely Partners
 
10.3.2. Key Non-Industry / Academic Partners
10.3.2.1. Most Likely Partners
10.3.2.2. Likely Partners
10.3.2.3. Less Likely Partners
 
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall CRISPR-based Genome Editing Services Market, 2019-2030
11.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-2030
11.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-2030
11.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-2030
11.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-2030
11.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-2030
 
11.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-2030
11.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-2030
11.5.1.1. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, 2019-2030
11.5.1.2. CRISPR-based Genome Editing Services Market for gRNA Construction in Europe, 2019-2030
11.5.1.3. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, 2019-2030
11.5.1.4. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, 2019-2030
 
11.6.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-2030
11.6.1.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering in North America, 2019-2030
11.6.1.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Europe, 2019-2030
11.6.1.3. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Asia Pacific, 2019-2030
11.6.1.4. 
 
11.7.1. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-2030
11.7.1.1. CRISPR-based Genome Editing Services Market for Animal Model Generation in North America, 2019-2030
11.7.1.2. CRISPR-based Genome Editing Services Market for Animal Model Generation in Europe, 2019-2030
11.7.1.3. CRISPR-based Genome Editing Services Market for Animal Model Generation in Asia Pacific, 2019-2030
11.7.1.4. CRISPR-based Genome Editing Services Market for Animal Model Generation in Rest of the World, 2019-2030
 
11.8. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-2030
11.8.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-2030
11.8.1.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in North America, 2019-2030
11.8.1.2. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Europe, 2019-2030
11.8.1.3. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Asia Pacific, 2019-2030
11.8.1.4. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Rest of the World, 2019-2030
 
11.9.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-2030
11.9.1.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in North America, 2019-2030
11.9.1.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Europe, 2019-2030
11.9.1.3. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Asia Pacific, 2019-2030
11.9.1.4. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Rest of the World, 2019-2030
 
11.10.1. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030
11.10.1.1. CRISPR-based Genome Editing Services Market for Other Cell Lines in North America, 2019-2030
11.10.1.2. CRISPR-based Genome Editing Services Market for Other Cell Lines in Europe, 2019-2030
11.10.1.3. CRISPR-based Genome Editing Services Market for Other Cell Lines in Asia Pacific, 2019-2030
11.10.1.4. CRISPR-based Genome Editing Services Market for Other Cell Lines in Rest of the World, 2019-2030
 
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. SWOT Analysis
12.2.1. Strengths
12.2.2. Weaknesses
12.2.3. Opportunities
12.2.4. Threats
12.2.5. Concluding Remarks
 
13. EXECUTIVE INSIGHTS
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Genome Editing: Historical Milestones
Figure 3.2. Genome Editing Techniques
Figure 3.3. CRISPR-based Genome Editing Protocol
Figure 4.1. CRISPR-based Genome Editing Services: Distribution by Type of Service Offering
Figure 4.2. CRISPR-based Genome Editing Services: Distribution by Type of gRNA Format
Figure 4.3. CRISPR-based Genome Editing Services: Distribution by Type of Endonuclease
Figure 4.4. CRISPR-based Genome Editing Services: Distribution by Type of Cas9 Endonuclease Format
Figure 4.5. CRISPR-based Genome Editing Services: Distribution by Type of Cell Line Engineering
Figure 4.6. CRISPR-based Genome Editing Services: Distribution by Type of Animal Model Generation
Figure 4.7. CRISPR-based Genome Editing Services: Distribution by Availability of CRISPR Libraries
Figure 4.8. CRISPR-based Genome Editing Service Providers: Distribution by Year of Establishment
Figure 4.9. CRISPR-based Genome Editing Service Providers: Distribution by Company Size
Figure 4.10. CRISPR-based Genome Editing Service Providers: Distribution by Geographical Location
Figure 4.11. CRISPR-based Genome Editing Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
Figure 5.1. Company Competitiveness Analysis: Assumptions and Key Parameters
Figure 5.2. Company Competitiveness Analysis: Small-sized Players
Figure 5.3. Company Competitiveness Analysis: Mid-sized Players
Figure 5.4. Company Competitiveness Analysis: Large Players
Figure 6.1. Charles River Laboratories: Annual Revenues, 2014–H1 2019 (USD Billion)
Figure 6.2. Horizon Discovery: Annual Revenues, 2014-H1 2019 (EUR Million)
Figure 6.3. Thermo Fisher Scientific: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 7.1. Patent Portfolio: Distribution by Type of Patent
Figure 7.2. Patent Portfolio: Distribution by Application Year
Figure 7.3. Patent Portfolio: Distribution by Publication Year
Figure 7.4. Patent Portfolio: Distribution by Geography
Figure 7.5. Patent Portfolio: Distribution by CPC Symbols
Figure 7.6. Patent Portfolio: Emerging Focus Areas
Figure 7.7. Leading Industry Players: Distribution by Size of Patent Portfolio
Figure 7.8. Leading Non-Industry Players: Distribution by Size of Patent Portfolio
Figure 7.9. Patent Portfolio: Benchmarking by Patent Characteristics
Figure 7.10. Patent Portfolio: Valuation Analysis
Figure 8.1. Academic Grant Analysis: Year-wise Trend of Award
Figure 8.2. Academic Grant Analysis: Distribution by Amount Awarded
Figure 8.3. Academic Grant Analysis: Distribution by Administering Institutes
Figure 8.4. Academic Grant Analysis: Distribution by Support Period
Figure 8.5. Academic Grant Analysis: Distribution by Funding Mechanism
Figure 8.6. Academic Grant Analysis: Distribution by Type of Grant Application
Figure 8.7. Academic Grant Analysis: Distribution by Grant Activity
Figure 8.8. Academic Grant Analysis: Distribution by Recipient Organization
Figure 8.9. Academic Grant Analysis: Regional Distribution of Recipient Organization
Figure 8.10. Prominent Project Leaders: Distribution by Number of Grants Awarded
Figure 8.11. Academic Grant Analysis: Emerging Focus Areas
Figure 8.12. Academic Grant Analysis: Grant Attractiveness Analysis
Figure 9.1. CRISPR-based Technology Providers: Distribution by Year of Establishment
Figure 9.2. CRISPR-based Technology Providers: Distribution by Company Size
Figure 9.3. CRISPR-based Technology Providers: Distribution by Geographical Location and Company Expertise
Figure 9.4. CRISPR-based Technology Providers: Distribution by Focus Area
Figure 9.5. Key CRISPR-based Technology Providers: Venture Capital Investments (USD Million)
Figure 11.1. Overall CRISPR-based Genome Editing Services Market, 2019-2030 (USD Million)
Figure 11.2. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-2030 (USD Million)
Figure 11.3. CRISPR-based Genome Editing Services Market in North America, 2019-2030 (USD Million)
Figure 11.4. CRISPR-based Genome Editing Services Market in Europe, 2019-2030 (USD Million)
Figure 11.5. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-2030 (USD Million)
Figure 11.6. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-2030 (USD Million)
Figure 11.7. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-2030 (USD Million)
Figure 11.8. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-2030 (USD Million)
Figure 11.9. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, 2019-2030 (USD Million)
Figure 11.10. CRISPR-based Genome Editing Services Market for gRNA Construction in
Figure 11.11. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, 2019-2030 (USD Million)
Figure 11.12. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, 2019-2030 (USD Million)
Figure 11.13. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-2030 (USD Million)
Figure 11.14. CRISPR-based Genome Editing Services Market for Cell Line Engineering in North America, 2019-2030 (USD Million)
Figure 11.15. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Europe, 2019-2030 (USD Million)
Figure 11.16. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Asia Pacific, 2019-2030 (USD Million)
Figure 11.17. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Rest of the World, 2019-2030 (USD Million)
Figure 11.18. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-2030 (USD Million)
Figure 11.19. CRISPR-based Genome Editing Services Market for Animal Model Generation in North America, 2019-2030 (USD Million)
Figure 11.20. CRISPR-based Genome Editing Services Market for Animal Model Generation in Europe, 2019-2030 (USD Million)
Figure 11.21. CRISPR-based Genome Editing Services Market for Animal Model Generation in Asia Pacific, 2019-2030 (USD Million)
Figure 11.22. CRISPR-based Genome Editing Services Market for Animal Model Generation in Rest of the World, 2019-2030 (USD Million)
Figure 11.23. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-2030 (USD Million)
Figure 11.24. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-2030 (USD Million)
Figure 11.25. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in North America, 2019-2030 (USD Million)
Figure 11.26. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Europe, 2019-2030 (USD Million)
Figure 11.27. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Asia Pacific, 2019-2030 (USD Million)
Figure 11.28. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Rest of the World, 2019-2030 (USD Million)
Figure 11.29. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-2030 (USD Million)
Figure 11.30. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in North America, 2019-2030 (USD Million)
Figure 11.31. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Europe, 2019-2030 (USD Million)
Figure 11.32. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Asia Pacific, 2019-2030 (USD Million)
Figure 11.33. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Rest of the World, 2019-2030 (USD Million)
Figure 11.34. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030 (USD Million)
Figure 11.35. CRISPR-based Genome Editing Services Market for Other Cell Lines in North America, 2019-2030 (USD Million)
Figure 11.36. CRISPR-based Genome Editing Services Market for Other Cell Lines in Europe, 2019-2030 (USD Million)
Figure 11.37. CRISPR-based Genome Editing Services Market for Other Cell Lines in Asia Pacific, 2019-2030 (USD Million)
Figure 11.38. CRISPR-based Genome Editing Services Market for Other Cell Lines in Rest of the World, 2019-2030 (USD Million)
Figure 12.1. CRISPR-based Genome Editing: SWOT Factors
Figure 12.2. Comparison of SWOT Factors: Harvey Ball Analysis

List of Tables

Table 3.1. Classification of CRISPR-Cas Systems
Table 4.1. List of CRISPR-based Genome Editing Service Providers: Information on Type of Service
Table 4.2. List of CRISPR-based Genome Editing Service Providers: Information on gRNA Format, Type of Endonuclease and Cas9 Endonuclease Format
Table 4.3. List of CRISPR-based Genome Editing Service Providers: Information on Cell Line Engineering Offerings, Animal Model Generation Offerings and Availability of CRISPR Libraries
Table 5.1. Company Competitive Analysis: Small-sized Players
Table 5.2. Company Competitive Analysis: Mid-sized Players
Table 5.3. Company Competitive Analysis: Large Players
Table 6.1. CRISPR-based Genome Editing Services Providers: List of Companies Profiled
Table 6.2. Applied StemCell: Company Overview
Table 6.3. Applied StemCell: CRISPR-based Genome Editing Services
Table 6.4. Applied StemCell: Recent Developments and Future Outlook
Table 6.5. BioCat: Company Overview
Table 6.6. BioCat: CRISPR-based Genome Editing Services
Table 6.7. BioCat: Recent Developments and Future Outlook
Table 6.8. Charles River Laboratories: Company Overview
Table 6.9. Charles River Laboratories: CRISPR-based Genome Editing Services
Table 6.10. Charles River Laboratories: Recent Developments and Future Outlook
Table 6.11. Cobo Scientific: Company Overview
Table 6.12. Cobo Scientific: CRISPR-based Genome Editing Services
Table 6.13. Cobo Scientific: Recent Developments and Future Outlook
Table 6.14. Creative Biogene: Company Overview
Table 6.15. Creative Biogene: CRISPR-based Genome Editing Services
Table 6.16. Creative Biogene: Recent Developments and Future Outlook
Table 6.17. Cyagen Biosciences: Company Overview
Table 6.18. Cyagen Biosciences: CRISPR-based Genome Editing Services
Table 6.19. Cyagen Biosciences: Recent Developments and Future Outlook
Table 6.20. GeneCopoeia: Company Overview
Table 6.21. GeneCopoeia: CRISPR-based Genome Editing Services
Table 6.22. GeneCopoeia: Recent Developments and Future Outlook
Table 6.23. Horizon Discovery: Company Overview
Table 6.24. Horizon Discovery: CRISPR-based Genome Editing Services
Table 6.25. Horizon Discovery: Recent Developments and Future Outlook
Table 6.26. NemaMetrix: Company Overview
Table 6.27. NemaMetrix: CRISPR-based Genome Editing Services
Table 6.28. NemaMetrix: Recent Developments and Future Outlook
Table 6.29. Synbio Technologies: Company Overview
Table 6.30. Synbio Technologies: CRISPR-based Genome Editing Services
Table 6.31. Synbio Technologies: Recent Developments and Future Outlook
Table 6.32. Thermo Fisher Scientific: Company Overview
Table 6.33. Thermo Fisher Scientific: CRISPR-based Genome Editing Services
Table 6.34. Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.1. Grant Analysis: List of Most Attractive Grants
Table 9.1. List of CRISPR-based Technology Providers
Table 9.2. List of CRISPR-based Technology Providers: Information on Technology
Table 9.3. Beam Therapeutics: Funding Instances
Table 9.4. Beam Therapeutics: Collaborations
Table 9.5. CRISPR Therapeutics: Funding Instances
Table 9.6. CRISPR Therapeutics: Collaborations
Table 9.7. Editas Medicine: Funding Instances
Table 9.8. Editas Medicine: Collaborations
Table 9.9. KSQ Therapeutics: Funding Instances
Table 9.10. Locus Biosciences: Funding Instances
Table 9.11. Locus Biosciences: Collaborations
Table 9.12. Refuge Biotechnologies: Funding Instances
Table 9.13. Refuge Biotechnologies: Collaborations
Table 9.14. Repare Therapeutics: Funding Instances
Table 9.15. SNIPR BIOME: Funding Instances
Table 9.16. Intellia Therapeutics: Funding Instances
Table 9.17. Intellia Therapeutics: Collaborations
Table 9.18. List of CRISPR Kit Providers
Table 9.19. List of CRISPR Design Tool Providers
Table 10.1. Industry Players: Most Likely Partners
Table 10.2. Industry Players: Likely Partners
Table 10.3. Industry Players: Less Likely Partners
Table 10.4. Non-Industry Players: Most Likely Partners
Table 10.5. Non-Industry Players: Likely Partners
Table 10.6. Non-Industry Players: Less Likely Partners
Table 14.1. CRISPR-based Genome Editing Services: Distribution by Type of Service Offering
Table 14.2. CRISPR-based Genome Editing Services: Distribution by Type of gRNA Format
Table 14.3. CRISPR-based Genome Editing Services: Distribution by Type of Endonuclease
Table 14.4. CRISPR-based Genome Editing Services: Distribution by Type of Cas9 Endonuclease Format
Table 14.5. CRISPR-based Genome Editing Services: Distribution by Type of Cell Line Engineering
Table 14.6. CRISPR-based Genome Editing Services: Distribution by Type of Animal Model Generation
Table 14.7. CRISPR-based Genome Editing Services: Distribution by Availability of CRISPR Libraries
Table 14.8. CRISPR-based Genome Editing Service Providers: Distribution by Year of Establishment
Table 14.9. CRISPR-based Genome Editing Service Providers: Distribution by Company Size
Table 14.10. CRISPR-based Genome Editing Service Providers: Distribution by Geographical Location
Table 14.11. CRISPR-based Genome Editing Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
Table 14.12. Charles River Laboratories: Annual Revenues, 2014–H1 2019 (USD Billion)
Table 14.13. Horizon Discovery: Annual Revenues, 2014-H1 2019 (EUR Million)
Table 14.14. Thermo Fisher Scientific: Annual Revenues, 2014-H1 2019 (USD Million)
Table 14.15. Patent Portfolio: Distribution by Type of Patent
Table 14.16. Patent Portfolio: Distribution by Application Year
Table 14.17. Patent Portfolio: Distribution by Publication Year
Table 14.18. Patent Portfolio: Distribution by Geography
Table 14.19. Leading Industry Players: Distribution by Size of Patent Portfolio
Table 14.20. Leading Non-Industry Players: Distribution by Size of Patent Portfolio
Table 14.21. Patent Portfolio: Valuation Analysis
Table 14.22. Academic Grant Analysis: Year-wise Trend of Award
Table 14.23. Academic Grant Analysis: Distribution by Amount Awarded
Table 14.24. Academic Grant Analysis: Distribution by Administering Institutes
Table 14.25. Academic Grant Analysis: Distribution by Support Period
Table 14.26. Academic Grant Analysis: Distribution by Funding Mechanism
Table 14.27. Academic Grant Analysis: Distribution by Type of Grant Application
Table 14.28. Academic Grant Analysis: Distribution by Grant Activity
Table 14.29. Academic Grant Analysis: Distribution by Recipient Organization
Table 14.30. Prominent Project Leaders: Distribution by Number of Grants Awarded
Table 14.31. Academic Grant Analysis: Grant Attractiveness Analysis
Table 14.32. CRISPR-based Technology Providers: Distribution by Year of Establishment
Table 14.33. CRISPR-based Technology Providers: Distribution by Company Size
Table 14.34. CRISPR-based Technology Providers: Distribution by Focus Area
Table 14.35. Key CRISPR-based Technology Providers: Venture Capital Investments (USD Million)
Table 14.36. Overall CRISPR-based Genome Editing Services Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.37. CRISPR-based Genome Editing Services Market: Distribution by Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.38. CRISPR-based Genome Editing Services Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.39. CRISPR-based Genome Editing Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.40. CRISPR-based Genome Editing Services Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.41. CRISPR-based Genome Editing Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.42. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.43. CRISPR-based Genome Editing Services Market for gRNA Construction, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.44. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.45. CRISPR-based Genome Editing Services Market for gRNA Construction in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.46. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.47. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.48. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.49. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.50. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.51. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.52. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.53. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.54. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.55. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.56. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.57. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.58. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.59. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.60. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.61. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.62. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.63. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.64. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.65. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.66. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.67. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.68. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.69. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.70. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.71. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.72. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.73. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)

List of Companies

1. 302 Military Hospital of China
2. 4D Molecular Therapeutics
3. AAVogen
4. AB SCIEX 
5. AbbVie
6. AbCheck
7. AbClon
8. Abeona Therapeutics 
9. ACROBiosystems
10. Actus Therapeutics
11. Acucela
12. Adaptimmune Therapeutics
13. Adicet Bio
14. Advantagene
15. Advaxis
16. Adverum Biotechnologies
17. Adverum Biotechnologies
18. Aeon Therapeutics
19. Affiliated Hospital to Academy of Military Medical Sciences
20. Agency for Science, Technology and Research (A*STAR)
21. AgenTus Therapeutics
22. Agilent Technologies
23. Agilis Biotherapeutics
24. Akouos
25. Albert Einstein College of Medicine
26. Aldevron
27. Alex's Lemonade Stand Foundation
28. Allergan
29. Allife Medical Science and Technology
30. Allogene Therapeutics
31. AlphaVax
32. ALSTEM
33. Altor Bioscience
34. American Gene Technologies
35. Amgen
36. Amicus Therapeutics
37. AMS Biotechnology
38. Anaeropharma Science
39. Analytical Biological Services
40. Anchiano Therapeutics
41. AnGes
42. Angionetics
43. Anhui Provincial Hospital
44. Animalab
45. Antagene
46. Antibody Design Labs
47. Apic Bio
48. Applied Biological Materials (abm)
49. Applied Genetic Technologies (AGTC)
50. Applied StemCell
51. APSIS Therapeutics
52. ARBELE
53. Arbor Biosciences
54. Arthrogen
55. Aruvant Sciences
56. AskBio
57. Astellas Pharma
58. Atara Biotherapeutics
59. Atossa Genetics
60. Atreca
61. ATUM
62. Auburn University
63. Audentes Therapeutics
64. AuraGen
65. Aurora Biopharma
66. Autolus
67. Avacta
68. Avectas
69. AveXis
70. AVROBIO
71. Axol Bioscience
72. Axovant Gene Therapies
73. Bamboo Therapeutics
74. Baxter
75. Bayer
76. Baylor College of Medicine
77. Beam Therapeutics
78. Beijing Biohealthcare Biotechnology
79. Beijing Cancer Hospital
80. Beijing Doing Biomedical
81. Beijing Immunochina Medical Science & Technology
82. Beijing Lu Daopei Hospital
83. Beijing Mario Biotech
84. Beijing Sanbo Brain Hospital
85. Beijing Sanwater Biological Technology
86. Bellicum Pharmaceuticals
87. Benchling
88. Berlin Institute of Health
89. Bill & Melinda Gates Foundation
90. BioAtla
91. BioCat
92. Bioceltech Therapeutics
93. BioChain
94. Biocodon Technologies
95. Biocytogen
96. Biogen
97. BioInvent
98. Biolegio
99. Biologics International
100. BioMarin
101. Bioneer
102. Bionic Sight
103. BioNTech
104. Biotools
105. Bioverativ
106. Blue Heron Biotech
107. bluebird bio
108. B-MoGen Biotechnologies
109. Boehringer Ingelheim
110. Boston Children's Hospital
111. Bristol-Myers Squibb
112. Broad Institute 
113. Brown University
114. Butterfly sciences
115. California Institute for Regenerative Medicine
116. California Institute of Technology
117. Calimmune
118. Cambridge Bioscience
119. Cancer Research UK
120. Canopy BioSciences
121. Captain T Cell
122. Cardiogen Sciences
123. Caribou Biosciences
124. Carina Biotech
125. CARsgen Therapeutics
126. Cartesian Therapeutics
127. Cartherics
128. Case Comprehensive Cancer Center
129. CASPR Biotech
130. Castle Creek Pharma
131. Celenex
132. Celgene
133. Cell and Gene Therapy Catapult
134. Cell Medica
135. Cellecta
136. Cellectis
137. CellGenTech
138. CellSystems
139. Cellular Biomedicine Group
140. Cellular Therapeutics
141. Celsion
142. Celvab
143. Celyad
144. Center for Applied Medical Research (CIMA)
145. Center for Cell and Gene Therapy
146. Changhai Hospital
147. Changzheng Hospital
148. Charles River Laboratories
149. Chatham Therapeutics
150. Chiba University
151. Children's Hospital and Health System Foundation
152. Children's Hospital of Fudan University
153. Children's Hospital of Philadelphia
154. Children's Mercy Kansas City
155. China Immunotech
156. China Meitan General Hospital
157. Chinese Academy of Sciences
158. Chinese PLA General Hospital
159. City of Hope National Medical Center
160. Cobo Scientific
161. Coderegenesis 
162. Cold Genesys
163. CombiGene
164. Copernicus Therapeutics
165. Cosmo Bio
166. Creative Bioarray
167. Creative Biogene
168. CRISPR Therapeutics
169. CrownBio
170. CSL Behring
171. Cyagen
172. Cynvec
173. Cytovant Sciences
174. Daiichi Sankyo
175. Dana-Farber Cancer Institute
176. Defense Advanced Research Projects Agency (DARPA)
177. DefiniGEN
178. Desktop Genetics
179. Dimension Therapeutics
180. Discovery Genomics
181. DNAlite Therapeutics
182. DNAtrix
183. Dongguan People's Hospital
184. Dow AgroSciences
185. Duke University Medical Center
186. Duke-NUS Medical School
187. EdiGene
188. Editas Medicine
189. eGenesis Bio
190. Ehime University
191. Eli Lilly
192. Endocyte
193. Endsulin
194. Enochian BioSciences
195. Entos Pharmaceuticals
196. Epeius Biotechnologies
197. Errant Gene Therapeutics
198. ERS Genomics
199. Esteve
200. Eureka Therapeutics
201. Eutilex
202. Exonics Therapeutics
203. ExpressCells
204. Expression Therapeutics
205. EXUMA Biotechnology
206. Eyevensys
207. F1 Oncology
208. Fate Therapeutics
209. Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology
210. Fibrocell
211. First Affiliated Hospital of Chengdu Medical College
212. First Affiliated Hospital of Guangdong Pharmaceutical University
213. First Affiliated Hospital of Zhejiang University
214. First People's Hospital of Foshan
215. First People's Hospital of Yunnan
216. FIT Biotech
217. Five Prime Therapeutics
218. FKD Therapies
219. Flexion Therapeutics
220. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
221. Forevertek Biotechnology
222. Formula Pharmaceuticals
223. Fosun Pharma
224. Fred Hutchinson Cancer Research Center
225. Freeline Therapeutics
226. Fuda Cancer Hospital
227. Fudan University
228. Fujian Cancer Hospital
229. Fujian Medical University
230. Fujita Health University
231. Fulcrum Therapeutics 
232. Gadeta
233. GEG Tech
234. Gemini Therapeutics
235. Genable Technologies
236. GenAhead Bio
237. GeneCopoeia
238. GeneCure Biotechnologies
239. GenEdit
240. Genelux
241. Genentech
242. GeneOne Life Science
243. GenePharma
244. GeneQuine Biotherapeutics
245. Generation Bio
246. Genethon
247. Genetics Research
248. GENEWIZ 
249. Genexine 
250. Genmab
251. genOway
252. Genprex
253. GenScript
254. GenSight Biologics
255. Genus Oncology
256. GenVec
257. German Cancer Research Center
258. GigaGen
259. GlaxoSmithKline
260. Glycostem
261. Gracell Biotechnologies
262. Gradalis
263. Green Cross Cell
264. GSK
265. Guangdong General Hospital
266. Guangdong Xiangxue Precision Medical Technology
267. Guangdong Zhaotai InVivo Biomedicine
268. Guangzhou Anjie Biomedical Technology
269. Guangzhou Doublle Bioproducts
270. Guangzhou Eighth People's Hospital
271. Guangzhou FineImmune Biotechnology
272. Guangzhou First People's Hospital
273. Guangzhou Yi Yan Biological Technology
274. Gynecologic Oncology Group Foundation
275. Gyroscope Therapeutics
276. Hanyang University
277. Harvard College
278. Harvard University
279. Hebei Senlang Biotechnology
280. Hebei Yanda Ludaopei Hospital
281. Hefei Binhu Hospital
282. Heidelberg University
283. Helix BioPharma
284. Helixmith 
285. Hemera Biosciences
286. Henan Cancer Hospital
287. Henan Hualong Biotechnology
288. Herantis Pharma
289. Histogenics
290. Holostem Terapie Avanzate
291. Homology Medicines
292. HORAMA
293. Horizon Discovery
294. Hrain Biotechnology
295. Huaian First People's Hospital
296. Huazhong Agricultural University
297. Huazhong University of Science and Technology
298. Human Stem Cells Institute 
299. Hunan Provincial People's Hospital
300. Hunan Yongren Medical Innovation
301. Hunan Zhaotai Yongren Biotech
302. Hunterian Medicine 
303. Icahn School of Medicine at Mount Sinai
304. iCAR Bio Therapeutics
305. iCarTAB BioMed
306. iCell Gene Therapeutics
307. Icell Kealex Therapeutics
308. ICON
309. IDeal Genetics
310. i-DNA Biotechnology
311. ILPEN Scientific Equipment & Supplies
312. Immatics
313. Immune Therapeutics
314. Immunocore
315. ImmunoGenes
316. Immusoft
317. ingenious targeting laboratory
318. Innovative Cellular Therapeutics
319. Inotek Pharmaceuticals
320. Inovio Pharmaceuticals
321. Inscripta
322. Institute of Hematology & Blood Diseases Hospital
323. Integrated DNA Technologies 
324. Intellia Therapeutics
325. Intrexon
326. Invectys
327. Iowa State University
328. IVERIC bio
329. IWK Health Centre is affiliated to Dalhousie University, to be added as separate entries 
330. Janssen Pharmaceuticals
331. Jennerex Biotherapeutics
332. Jenthera Therapeutics
333. Jichi Medical University
334. Jingzhou Central Hospital
335. Johns Hopkins Kimmel Cancer Center
336. Jonsson Comprehensive Cancer Center
337. Juno Therapeutics
338. Juventas Therapeutics
339. JW Biotechnology
340. KAEDI
341. King's College London
342. Kite Pharma
343. Kolon TissueGene
344. Krystal Biotech
345. KSQ Therapeutics
346. Labomics
347. Lacerta Therapeutics
348. Leiden University Medical Center
349. Leland Stanford Junior University 
350. Leucid Bio
351. LifeEDIT
352. Ligandal
353. Liminatus Pharma
354. Lion TCR
355. Living Pharma
356. Locus Biosciences
357. LogicBio Therapeutics
358. Lokon Pharma
359. Lonza
360. Loop Genomics
361. Loyola University
362. LubioScience
363. Lucigen
364. Ludwig Cancer Research
365. Lysogene
366. MabVax Therapeutics
367. Macrogen
368. Mammoth Biosciences
369. Marino Biotechnology
370. Marsala Biotech
371. Massachusetts General Hospital
372. Massachusetts Institute of Technology
373. MaxCyte
374. Mayo Clinic
375. MD Anderson Cancer Center
376. Medical College of Wisconsin
377. Medigene
378. MedImmune
379. Medisix Therapeutics
380. MeiraGTx
381. Memorial Sloan Kettering Cancer Center
382. Merck
383. Mesoblast
384. Microsynth
385. Mie University Hospital
386. Milo Biotechnology
387. Miltenyi Biotec
388. Minerva Biotechnologies
389. MingJu Therapeutics
390. Mirimus
391. Moffitt Cancer Center
392. MolMed
393. Momotaro-Gene
394. Monsanto
395. MultiVir
396. Mustang Bio
397. Myonexus Therapeutics
398. Nagoya University
399. Nanfang Hospital of Southern Medical University
400. Nanjing Children's Hospital
401. Nanjing Legend Biotech
402. NanoCor Therapeutics
403. Nanogenics
404. Nanosens Innovations
405. National Cancer Institute
406. National Eye Institute
407. National Heart, Lung, and Blood Institute
408. National Human Genome Research Institute 
409. National Institute of Aging
410. National Institute of Allergy and Infectious Diseases
411. National Institute of Arthritis and Musculoskeletal and Skin Diseases
412. National Institute of Child Health and Human Development
413. National Institute of Diabetes and Digestive and Kidney Diseases
414. National Institute of General Medical Sciences
415. National Institute of Mental Health
416. National Institute of Neurological Disorders and Stroke
417. National Institute on Drug Abuse
418. National Institutes of Health
419. Nationwide Children's Hospital
420. Navy General Hospital
421. Ncardia
422. NemaMetrix
423. Neuracle Genetics
424. Neuralgene
425. Neurocrine Biosciences
426. Neurogene
427. New England Biolabs
428. Nightstar Therapeutics
429. Ningbo Cancer Hospital
430. NIPRO
431. NMI TT Pharmaservices
432. Noahgen
433. Nohla Therapeutics
434. Noile-Immune Biotech
435. Novartis
436. NTrans Technologies
437. Obsidian Therapeutics
438. Ocugen
439. omicX
440. Oncolys BioPharma
441. Oncos Therapeutics
442. OncoSec Medical
443. Orbit Biomedical
444. ORCA Therapeutics
445. Orchard Therapeutics
446. OriGene Technologies
447. Ottawa Hospital Research Institute
448. Oxford BioMedica
449. Oxford Genetics
450. OZ Biosciences
451. Pacific Biosciences
452. Parker Institute for Cancer Immunotherapy
453. Passage Bio
454. Pattern BioSciences
455. Peking University
456. PeproMene Bio
457. PeriphaGen
458. PersonGen BioTherapeutics
459. Peter MacCallum Cancer Centre
460. Pfizer
461. PHENOMIN-ICS
462. Pinze Lifetechnology
463. Pioneer Hi-Bred International
464. PlasmaTech Biopharmaceuticals
465. PNA Bio
466. PolyGene
467. Poseida Therapeutics
468. Precigen
469. Precision BioSciences
470. Precision Genome Engineering
471. Precision Virologics
472. Prevail Therapeutics
473. Promab Biotechnologies
474. Promega
475. Promethera Biosciences
476. Protheragen
477. PsiOxus Therapeutics
478. PTC Therapeutics
479. Purdue University
480. Qingdao Central Hospital
481. Quethera 
482. Recombinetics
483. Refuge Biotechnologies
484. Regeneron Pharmaceuticals
485. REGENXBIO
486. RenJi Hospital
487. Renova Therapeutics
488. Rentschler Biopharma
489. Repare Therapeutics
490. ReproCELL
491. RetroSense Therapeutics
492. Reyon Pharmaceutical
493. Roche
494. Rocket Pharmaceuticals
495. Rockland Immunochemicals
496. Roger Williams Medical Center
497. Roswell Park Cancer Institute
498. Royal Adelaide Hospital Cancer Centre
499. Ruijin Hospital
500. Ryboquin
501. San Raffaele Hospital
502. Sanct
503. Sangamo Therapeutics
504. Sanofi
505. Sarepta Therapeutics
506. SCANBUR
507. Scancell
508. SciGenom Labs
509. Scotia Biologics
510. Seattle Children's Hospital
511. Seattle Children's Research Institute
512. Seattle Genetics
513. Second Affiliated Hospital of Guangzhou Medical University
514. Second Affiliated Hospital of Xi'an Jiaotong University
515. Second Military Medical University
516. Second Xiangya Hospital of Central South University
517. Selecta Biosciences
518. Servier
519. Shanghai Bioray Laboratory
520. Shanghai Changzheng Hospital
521. Shanghai Children's Medical Center
522. Shanghai East Hospital
523. Shanghai GeneChem
524. Shanghai General Hospital
525. Shanghai International Medical Center
526. Shanghai Jiao Tong University School of Medicine
527. Shanghai Longyao Biotechnology
528. Shanghai Public Health Clinical Center
529. Shanghai Sinobioway Sunterra Biotech
530. Shanghai Sixth People's Hospital
531. Shanghai Sunway Biotech
532. Shanghai Tenth People's Hospital
533. Shanghai Tong Ren Hospital
534. Shanghai Tongji Hospital
535. Shanghai Unicar-Therapy Bio-medicine Technology
536. Sheba Medical Center
537. Shenzhen BinDeBio
538. Shenzhen Geno-immune Medical Institute
539. Shenzhen Institute for Innovation and Translational Medicine
540. Shenzhen Second People's Hospital
541. Sherlock Biosciences
542. Shionogi
543. Shire (acquired by Takeda Pharmaceutical)
544. Sibiono GeneTech
545. Sichuan University
546. Sidney Kimmel Cancer Center
547. Sigma Aldrich
548. SillaJen
549. Sinobioway Cell Therapy
550. SNIPR BIOME
551. Solid Biosciences
552. Sorrento Therapeutics
553. Southern Medical University
554. Southwest Hospital
555. Spanish National Centre for Biotechnology
556. Spark Therapeutics
557. Spindle Biotech
558. SR-TIGET
559. St. Jude Children's Research Hospital
560. Stanford University
561. STEMCELL Technologies
562. Stony Brook University
563. StrideBio
564. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
565. SunyBiotech
566. Super-T Cell Cancer Company
567. Syd Labs
568. Symvivo
569. Synbio Technologies
570. Syngenta Participations
571. Synthego
572. System Biosciences
573. Taconic Biosciences
574. Tactiva Therapeutics
575. Takara Bio
576. Takeda Pharmaceutical
577. Targazyme
578. Targovax
579. Tasly Biopharmaceuticals
580. Taxus Cardium Pharmaceuticals
581. TC BioPharm
582. TCR2 Therapeutics
583. TCRCure Biopharma
584. tebu-bio
585. Tenaya Therapeutics
586. Tessa Therapeutics
587. Texas Children's Hospital
588. The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
589. The Bambino Gesu` Children's Hospital
590. The Beijing Pregene Science and Technology
591. The Cancer Hospital of Yunnan
592. The First Affiliated Hospital of Anhui Medical University
593. The First Affiliated Hospital of Chongqing Medical University
594. The First Affiliated Hospital of Harbin Medical University
595. The First Affiliated Hospital of Jinan University
596. The First Affiliated Hospital of Soochow University
597. The First Affiliated Hospital of Wenzhou Medical University
598. The First Affiliated Hospital of Zhengzhou University
599. The First Affiliated Hospital with Nanjing Medical University
600. The First Hospital of Jilin University
601. The First People's Hospital of Hefei
602. The First People's Hospital of Yuhang District
603. The General Hospital of Western Theater Command
604. The Methodist Hospital System
605. The Netherlands Cancer Institute
606. The Pregene (ShenZhen) Biotechnology
607. The Second Affiliated Hospital of Hainan Medical University
608. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
609. The Second Hospital of Anhui Medical University
610. The Second Hospital of Hebei Medical University
611. The Second Hospital of Nanjing Medical University
612. The Second Military Medical University
613. The Sixth Affiliated Hospital of Wenzhou Medical University
614. The Third Affiliated Hospital of Southern Medical University
615. The University of Chicago
616. The Wistar Institute
617. TheraBiologics
618. THERAVECTYS
619. Thermo Fisher Scientific
620. Third Affiliated Hospital
621. Third Military Medical University
622. Thomas Jefferson University
623. THP Medical Products
624. Tianjin Medical University Cancer Institute and Hospital
625. Tianjin Mycure Medical Technology
626. Tianjin People's Hospital
627. TILT Therapeutics
628. Timmune Biotech
629. Tmunity Therapeutics
630. TNK Therapeutics, subsidiary of Sorrento Therapeutics
631. Tocagen
632. Tongji Hospital
633. Tongji Medical College
634. Tongji University School of Medicine
635. Toni Stephenson Lymphoma Center
636. ToolGen
637. Transgene
638. Transposagen Biopharmaceuticals
639. Trilink Biotechnologies
640. TxCell
641. UC Davis Medical Center
642. UK Cystic Fibrosis Gene Therapy Consortium
643. Ultragenyx Pharmaceutical
644. UNC Lineberger Comprehensive Cancer Center
645. Union Stem Cell & Gene Engineering
646. uniQure Biopharma
647. United States Department of Defense
648. Universal Cells
649. Universitat Autònoma de Barcelona
650. University Health Network
651. University Hospital Heidelberg
652. University Medical Center Utrecht
653. University of Bergen
654. University of California
655. University of Cologne
656. University of Connecticut
657. University of Florida
658. University of Georgia 
659. University of Massachusetts Medical School
660. University of Oxford
661. University of Pennsylvania
662. University of Southern California
663. University of Technology
664. University of Texas MD Anderson Cancer Center
665. University of Zurich
666. Unum Therapeutics
667. Uppsala University
668. Urovant Sciences
669. UT Southwestern Medical Center
670. V Foundation
671. ValueAct Capital Management
672. VBL Therapeutics
673. VCN Biosciences
674. Vector Neurosciences
675. VectorBuilder
676. Velaz
677. Vertex Pharmaceuticals
678. Verve Therapeutics
679. Vessl™
680. Vigene Biosciences
681. Virttu Biologics
682. Vivet Therapeutics
683. Vivo Bio Tech
684. Vor Biopharma
685. Voyager Therapeutics
686. Washington University
687. Weill Cornell Medical College
688. Welgen
689. West China Hospital
690. Wuhan Sian Medical Technology
691. Wuhan Union Hospital
692. WuXi AppTec
693. Wyvern Pharmaceuticals
694. Xiangxue Life Sciences
695. Xiangxue Pharmaceutical
696. Xiangyang Central Hospital
697. Xijing Hospital
698. Xinqiao Hospital
699. XpressBio
700. Xuanwu Hospital
701. Xuzhou Medical University
702. XyloCor Therapeutics
703. Yake Biotechnology
704. Yale University
705. Yamaguchi University Graduate School of Medicine
706. Yan'an Affiliated Hospital of Kunming Medical University
707. Yuanyi Biotechnology
708. ZeClinics
709. Zelluna Immunotherapy
710. ZenBio
711. Zhejiang University
712. Zhongshan Hospital
713. Zhujiang Hospital of Southern Medical University
714. Ziopharm Oncology